Physician profile
Robert J Homm
NPI 1518926096
$2,110.68
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,416 · 2020: $213 · 2021: $287 · 2022: $195.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $1,386.67 | 2019-2022 | |
| Abbvie INC. | $295.61 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $161.98 | 2019-2021 | |
| Coopersurgical, INC. | $93.71 | 2019-2021 | |
| Organon LLC | $89.19 | 2021-2022 | |
| Ascend Therapeutics US, LLC | $40.75 | 2020-2022 | |
| Emd Serono, INC. | $15.89 | 2021 | |
| Baxter Healthcare | $15.06 | 2021 | |
| Duchesnay USA Incorporated | $11.82 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Homm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.